US5994392A
(en)
|
1988-02-26 |
1999-11-30 |
Neuromedica, Inc. |
Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
|
US5268164A
(en)
*
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
US5545719A
(en)
*
|
1990-05-01 |
1996-08-13 |
Neuromedica, Inc. |
Nerve growth peptides
|
US5439884A
(en)
*
|
1992-07-27 |
1995-08-08 |
Oregon Regional Primate Research Center |
Method of controlling fertilization using bombesin or its agonist
|
PT679088E
(pt)
*
|
1992-09-29 |
2002-12-31 |
Inhale Therapeutic Syst |
Administracao pulmonar de fragmentos activos de hormona paratiroide
|
US5434137A
(en)
*
|
1993-05-10 |
1995-07-18 |
Black; Keith L. |
Method for selective opening of abnormal brain tissue capillaries
|
AU1947395A
(en)
*
|
1994-02-28 |
1995-09-11 |
Medinova Medical Consulting Gmbh |
Drug targeting system, method for preparing same and its use
|
US20030113273A1
(en)
*
|
1996-06-17 |
2003-06-19 |
Patton John S. |
Methods and compositions for pulmonary delivery of insulin
|
US6190691B1
(en)
|
1994-04-12 |
2001-02-20 |
Adolor Corporation |
Methods for treating inflammatory conditions
|
US5962477A
(en)
*
|
1994-04-12 |
1999-10-05 |
Adolor Corporation |
Screening methods for cytokine inhibitors
|
GB2288732B
(en)
*
|
1994-04-13 |
1998-04-29 |
Quadrant Holdings Cambridge |
Pharmaceutical compositions
|
US5585355A
(en)
*
|
1994-04-22 |
1996-12-17 |
Alkermes, Inc. |
Method for increasing blood-ocular barrier permeability with permeabilizer peptides
|
CN1073119C
(zh)
*
|
1994-05-18 |
2001-10-17 |
吸入治疗系统公司 |
干扰素干粉配方的方法及组合物
|
US6290991B1
(en)
*
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US6573282B1
(en)
|
1995-09-12 |
2003-06-03 |
Adolor Corporation |
Peripherally active anti-hyperalgesic opiates
|
US5849761A
(en)
*
|
1995-09-12 |
1998-12-15 |
Regents Of The University Of California |
Peripherally active anti-hyperalgesic opiates
|
WO1997041856A1
(en)
*
|
1996-05-08 |
1997-11-13 |
Massachusetts Institute Of Technology |
ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5752515A
(en)
*
|
1996-08-21 |
1998-05-19 |
Brigham & Women's Hospital |
Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
CA2277519A1
(en)
|
1997-01-10 |
1998-07-16 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
|
US20030035778A1
(en)
*
|
1997-07-14 |
2003-02-20 |
Robert Platz |
Methods and compositions for the dry powder formulation of interferon
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6309623B1
(en)
*
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US6225444B1
(en)
|
1998-02-10 |
2001-05-01 |
Protarga, Inc. |
Neuroprotective peptides and uses thereof
|
JP2002533353A
(ja)
*
|
1998-12-23 |
2002-10-08 |
シトスキャン サイエンシズ エルエルシー |
中枢及び末梢神経系疾患の治療のための組成物、スクリーニング方法及び治療方法
|
US6630120B1
(en)
|
1999-03-08 |
2003-10-07 |
Alkermes, Inc. |
Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
|
US7235583B1
(en)
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
US6774119B1
(en)
*
|
1999-04-26 |
2004-08-10 |
Cedars-Sinai Medical Center |
Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
|
DE60032255T2
(de)
|
1999-10-04 |
2007-06-28 |
Nektar Therapeutics Al, Corp., Huntsville |
Polymer-stabilisierte neuropeptide
|
JP2004508279A
(ja)
*
|
2000-01-26 |
2004-03-18 |
シーダース シナイ メディカル センター |
薬剤を異常脳領域及び/又は悪性腫瘍にデリバリーするためにカリウムチャンネル活性化を用いる方法
|
US20050153940A1
(en)
*
|
2000-01-26 |
2005-07-14 |
Cedars-Sinai Medical Center |
Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
US7018979B1
(en)
|
2000-01-26 |
2006-03-28 |
Cedars-Sinai Medical Center |
Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
US7235397B1
(en)
*
|
2000-04-14 |
2007-06-26 |
Gensys, Inc. |
Methods and compositions for culturing spirochete and treating spirochetal diseases
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
WO2001085136A2
(en)
|
2000-05-10 |
2001-11-15 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US8251986B2
(en)
|
2000-08-17 |
2012-08-28 |
Angiodynamics, Inc. |
Method of destroying tissue cells by eletroporation
|
EP1341548A4
(de)
*
|
2000-11-03 |
2006-06-14 |
Massachusetts Inst Technology |
VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
ES2387562T3
(es)
*
|
2001-03-23 |
2012-09-26 |
Luitpold Pharmaceuticals, Inc. |
Conjugados alcohol graso-medicamento
|
WO2002076402A2
(en)
*
|
2001-03-23 |
2002-10-03 |
Protarga, Inc. |
Fatty amine drug conjugates
|
US7211561B2
(en)
*
|
2001-10-12 |
2007-05-01 |
Cedars-Sinai Medical Center |
Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
|
JP2005514393A
(ja)
|
2001-12-19 |
2005-05-19 |
ネクター セラピューティクス |
アミノグリコシドの肺への供給
|
WO2004069857A2
(en)
*
|
2003-02-06 |
2004-08-19 |
Uutech Limited |
“peptides, compositions and uses thereof”
|
US7485706B2
(en)
*
|
2003-07-30 |
2009-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurodegenerative protein aggregation inhibition methods and compounds
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089502A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
JP2007538004A
(ja)
*
|
2004-03-18 |
2007-12-27 |
ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド |
シヌクレイノパチーを治療する方法
|
US20050288298A1
(en)
*
|
2004-03-18 |
2005-12-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
KR20070086334A
(ko)
*
|
2004-11-16 |
2007-08-27 |
리머릭 뉴로사이언스즈, 인크. |
통증을 치료하기 위한 방법 및 조성물
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
WO2006091542A2
(en)
*
|
2005-02-22 |
2006-08-31 |
Cedars-Sinai Medical Center |
Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
|
WO2007027559A2
(en)
|
2005-08-29 |
2007-03-08 |
Shashoua Victor E |
Neuroprotective and neurorestorative methods and compositions
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
EP2545919A1
(de)
|
2005-12-23 |
2013-01-16 |
Link Medicine Corporation |
Behandlung von Synucleinopathien
|
US20070259820A1
(en)
*
|
2006-05-03 |
2007-11-08 |
The Regents Of The University Of Michigan |
Methods and reagents for activating heat shock protein 70
|
EP2016097A2
(de)
|
2006-05-04 |
2009-01-21 |
Genentech, Inc. |
Verfahren und zusammensetzungen in verbindung mit zpa-polypeptiden
|
PL2046833T3
(pl)
|
2006-07-14 |
2014-01-31 |
Ac Immune Sa |
Humanizowane przeciwciało przeciw amyloidowi beta
|
TWI608014B
(zh)
|
2006-07-14 |
2017-12-11 |
Ac免疫公司 |
抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
AU2008267038B2
(en)
|
2007-06-12 |
2014-08-07 |
Ac Immune S.A. |
Humanized antibodies to amyloid beta
|
CA2690434C
(en)
|
2007-06-12 |
2018-05-22 |
Ac Immune S.A. |
Monoclonal anti beta amyloid antibody
|
SG178809A1
(en)
|
2007-10-05 |
2012-03-29 |
Genentech Inc |
Use of anti-amyloid beta antibody in ocular diseases
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
US10702326B2
(en)
|
2011-07-15 |
2020-07-07 |
Virginia Tech Intellectual Properties, Inc. |
Device and method for electroporation based treatment of stenosis of a tubular body part
|
US11272979B2
(en)
|
2008-04-29 |
2022-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
US9283051B2
(en)
|
2008-04-29 |
2016-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating a treatment volume for administering electrical-energy based therapies
|
AU2009243079A1
(en)
|
2008-04-29 |
2009-11-05 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation to create tissue scaffolds
|
US10117707B2
(en)
|
2008-04-29 |
2018-11-06 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
US8992517B2
(en)
|
2008-04-29 |
2015-03-31 |
Virginia Tech Intellectual Properties Inc. |
Irreversible electroporation to treat aberrant cell masses
|
US11254926B2
(en)
|
2008-04-29 |
2022-02-22 |
Virginia Tech Intellectual Properties, Inc. |
Devices and methods for high frequency electroporation
|
US10238447B2
(en)
|
2008-04-29 |
2019-03-26 |
Virginia Tech Intellectual Properties, Inc. |
System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
|
US9867652B2
(en)
|
2008-04-29 |
2018-01-16 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
|
US9198733B2
(en)
|
2008-04-29 |
2015-12-01 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for electroporation-based therapies
|
US10272178B2
(en)
|
2008-04-29 |
2019-04-30 |
Virginia Tech Intellectual Properties Inc. |
Methods for blood-brain barrier disruption using electrical energy
|
US10245098B2
(en)
|
2008-04-29 |
2019-04-02 |
Virginia Tech Intellectual Properties, Inc. |
Acute blood-brain barrier disruption using electrical energy based therapy
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
JP5913980B2
(ja)
|
2008-10-14 |
2016-05-11 |
ジェネンテック, インコーポレイテッド |
免疫グロブリン変異体及びその用途
|
EP2340040B1
(de)
|
2008-10-22 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Modulierung von axonen-degeneration
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
WO2010057006A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Link Medicine Corporation |
Azaquinolinone derivatives and uses thereof
|
WO2010059241A2
(en)
|
2008-11-20 |
2010-05-27 |
Cambria Pharmaceuticals, Inc. |
Treatment of amyotrophic lateral sclerosis
|
WO2010075548A2
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
WO2010085607A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Surmodics Pharmaceuticals, Inc. |
Continuous double emulsion process for making microparticles
|
US11638603B2
(en)
|
2009-04-09 |
2023-05-02 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
US11382681B2
(en)
|
2009-04-09 |
2022-07-12 |
Virginia Tech Intellectual Properties, Inc. |
Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
|
US20120046309A1
(en)
|
2009-05-05 |
2012-02-23 |
Northwestern University |
Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
|
WO2010138919A2
(en)
|
2009-05-28 |
2010-12-02 |
Angiodynamics, Inc. |
System and method for synchronizing energy delivery to the cardiac rhythm
|
SG176628A1
(en)
|
2009-06-05 |
2012-01-30 |
Link Medicine Corp |
Aminopyrrolidinone derivatives and uses thereof
|
US9895189B2
(en)
|
2009-06-19 |
2018-02-20 |
Angiodynamics, Inc. |
Methods of sterilization and treating infection using irreversible electroporation
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
EP3011970A3
(de)
|
2009-10-22 |
2016-06-08 |
F. Hoffmann-La Roche AG |
Modulation der axondegeneration
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
EP2509626B1
(de)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
|
AU2010329847A1
(en)
|
2009-12-11 |
2012-07-26 |
Genecode As |
Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
MY164579A
(en)
|
2010-07-30 |
2018-01-15 |
Ac Immune Sa |
Safe and functional humanized antibodies
|
WO2012020124A1
(en)
|
2010-08-12 |
2012-02-16 |
Ac Immune S.A. |
Vaccine engineering
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
WO2012045882A2
(en)
|
2010-10-07 |
2012-04-12 |
Ac Immune S.A. |
Pharmaceutical composition
|
WO2012051433A2
(en)
|
2010-10-13 |
2012-04-19 |
Angiodynamics, Inc. |
System and method for electrically ablating tissue of a patient
|
AR083561A1
(es)
|
2010-10-26 |
2013-03-06 |
Ac Immune Sa |
Preparacion de una construccion antigenica
|
US8772457B2
(en)
|
2010-11-10 |
2014-07-08 |
Genentech, Inc. |
BACE1 antibodies
|
WO2012088149A2
(en)
|
2010-12-20 |
2012-06-28 |
Virginia Tech Intellectual Properties, Inc. |
High-frequency electroporation for cancer therapy
|
JP6061922B2
(ja)
|
2011-06-22 |
2017-01-18 |
ザ ジェネラル ホスピタル コーポレイション |
プロテイノパチーの処置方法
|
US9078665B2
(en)
|
2011-09-28 |
2015-07-14 |
Angiodynamics, Inc. |
Multiple treatment zone ablation probe
|
KR101981351B1
(ko)
|
2011-10-07 |
2019-09-02 |
에이씨 이뮨 에스.에이. |
타우를 인식하는 포스포특이적 항체
|
CN103974709B
(zh)
|
2011-10-14 |
2016-12-14 |
霍夫曼-拉罗奇有限公司 |
Bace1的肽抑制剂
|
CN105063186A
(zh)
|
2011-11-10 |
2015-11-18 |
霍夫曼-拉罗奇有限公司 |
用于治疗、诊断和监测阿尔茨海默病的方法
|
EP2830643A1
(de)
|
2012-03-26 |
2015-02-04 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur prävention oder behandlung eines ischämiebedingten organschadens
|
AU2013243861A1
(en)
|
2012-04-05 |
2014-10-23 |
Ac Immune S.A. |
Humanized Tau antibody
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
IN2014MN02574A
(de)
|
2012-05-22 |
2015-07-24 |
Genentech Inc |
|
JP6267193B2
(ja)
|
2012-05-22 |
2018-01-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
置換ジピリジルアミン類及びそれらの使用
|
WO2014008458A2
(en)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
CA2883168A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
WO2014049047A1
(en)
|
2012-09-27 |
2014-04-03 |
F. Hoffmann-La Roche Ag |
Substituted sulfonamide compounds
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
JP6199991B2
(ja)
|
2013-01-18 |
2017-09-20 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
3置換ピラゾール及びdlk阻害剤としての使用
|
US9888956B2
(en)
|
2013-01-22 |
2018-02-13 |
Angiodynamics, Inc. |
Integrated pump and generator device and method of use
|
BR112015022488A2
(pt)
|
2013-03-14 |
2017-07-18 |
Genentech Inc |
triazolopiridinas substituídas e métodos de uso das mesmas
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
TWI622587B
(zh)
|
2013-05-01 |
2018-05-01 |
赫孚孟拉羅股份公司 |
二雜芳基化合物及其用途
|
WO2014177524A1
(en)
|
2013-05-01 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
C-linked heterocycloalkyl substituted pyrimidines and their uses
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
LT3055302T
(lt)
|
2013-10-11 |
2019-03-12 |
F. Hoffmann-La Roche Ag |
Pakeistieji heterocikliniai sulfonamidiniai junginiai, tinkami naudoti kaip trpa1 moduliatoriai
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US20160324989A1
(en)
*
|
2014-01-17 |
2016-11-10 |
Wake Forest University Health Sciences |
Methods for enhancing the delivery of active agents
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
AU2015259303B2
(en)
|
2014-05-12 |
2021-10-28 |
Arena, Christopher B. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
EP4116329A1
(de)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2-glykoantikörper und verwendungen davon
|
TWI717319B
(zh)
|
2014-05-27 |
2021-02-01 |
中央研究院 |
得自類桿菌屬之岩藻糖苷酶及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
EP3149036A4
(de)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20-glycoantikörper und verwendungen davon
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
EP3221349B1
(de)
|
2014-11-19 |
2020-11-04 |
Axon Neuroscience SE |
Humanisierte tau-antikörper bei alzheimer-krankheit
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
WO2016100325A1
(en)
|
2014-12-15 |
2016-06-23 |
Virginia Tech Intellectual Properties, Inc. |
Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CA2973886A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107406462B
(zh)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
三环dlk抑制剂及其用途
|
NZ737536A
(en)
|
2015-05-22 |
2019-04-26 |
Genentech Inc |
Substituted benzamides and methods of use thereof
|
EP3341353A1
(de)
|
2015-08-27 |
2018-07-04 |
Genentech, Inc. |
Therapeutische verbindungen und verfahren zur verwendung davon
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
WO2017091592A1
(en)
|
2015-11-25 |
2017-06-01 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
CA3007641C
(en)
|
2015-12-09 |
2023-10-17 |
Brandeis University |
Dbh inhibitors for treating or preventing memory loss
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
EP3854782A1
(de)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituierte benzamide und verfahren zur verwendung davon
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
WO2018015411A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
|
EP3487853B1
(de)
|
2016-07-20 |
2022-06-08 |
F. Hoffmann-La Roche AG |
Bicyclische prolinverbindungen
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
EP3526219B1
(de)
|
2016-10-17 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Bicyclische pyridonlactame und verfahren zur verwendung davon
|
US10905492B2
(en)
|
2016-11-17 |
2021-02-02 |
Angiodynamics, Inc. |
Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
|
EP3541414A4
(de)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
Konjugierte biologische moleküle, pharmazeutische zusammensetzungen und verfahren
|
JP7171567B2
(ja)
|
2016-11-28 |
2022-11-15 |
エフ.ホフマン-ラ ロシュ アーゲー |
一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
|
AR110282A1
(es)
|
2016-12-02 |
2019-03-13 |
Hoffmann La Roche |
Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
CN114874209A
(zh)
|
2017-03-07 |
2022-08-09 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
EP3601273B1
(de)
|
2017-03-24 |
2021-12-01 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamid-derivate als natriumkanalinhibitoren
|
MA49560A
(fr)
|
2017-07-14 |
2020-05-20 |
Hoffmann La Roche |
Composés cétoniques bicycliques et leurs procédés d'utilisation
|
EP3460057A1
(de)
|
2017-09-22 |
2019-03-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Kdac varianten und deren nutzung
|
RU2020114670A
(ru)
|
2017-10-11 |
2021-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Бициклические соединения для применения в качестве ингибиторов rip1 киназы
|
SG11202002877RA
(en)
|
2017-10-31 |
2020-04-29 |
Hoffmann La Roche |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
TWI805653B
(zh)
|
2017-11-30 |
2023-06-21 |
韓商韓美藥品股份有限公司 |
4-胺基-n-(1-((3-氯-2-氟苯基)胺基)-6-甲基異喹啉-5-基)噻吩并[3,2-d]嘧啶-7-甲醯胺之鹽及其結晶型
|
US11607537B2
(en)
|
2017-12-05 |
2023-03-21 |
Virginia Tech Intellectual Properties, Inc. |
Method for treating neurological disorders, including tumors, with electroporation
|
AU2018378622A1
(en)
|
2017-12-06 |
2020-05-28 |
Ovid Therapeutics Inc. |
Use of miR101 or miR128 in the treatment of seizure disorders
|
WO2019164778A1
(en)
|
2018-02-20 |
2019-08-29 |
Genentech, Inc. |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
|
EP3759098A1
(de)
|
2018-02-26 |
2021-01-06 |
Genentech, Inc. |
Pyridinsulfonamidverbindungen und deren verwendung gegen schmerz und verwandte störungen
|
US11925405B2
(en)
|
2018-03-13 |
2024-03-12 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
US11311329B2
(en)
|
2018-03-13 |
2022-04-26 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
CA3095443A1
(en)
|
2018-03-28 |
2019-10-03 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
JP2021519788A
(ja)
|
2018-03-30 |
2021-08-12 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
|
CN112074519A
(zh)
|
2018-04-20 |
2020-12-11 |
豪夫迈·罗氏有限公司 |
作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
EP3847154A1
(de)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamid- und sulfonamidderivate zur verwendung als tead-modulatoren
|
WO2020146615A1
(en)
|
2019-01-11 |
2020-07-16 |
Genentech, Inc. |
Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
|
US11950835B2
(en)
|
2019-06-28 |
2024-04-09 |
Virginia Tech Intellectual Properties, Inc. |
Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
|
KR20220042429A
(ko)
|
2019-09-06 |
2022-04-05 |
리겔 파마슈티칼스, 인크. |
Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
|
TW202122397A
(zh)
|
2019-09-06 |
2021-06-16 |
美商雷傑製藥公司 |
Rip1抑制性化合物及用於製備和使用其之方法
|
CN115298184A
(zh)
|
2019-11-07 |
2022-11-04 |
里格尔药品股份有限公司 |
杂环rip1抑制化合物
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
CA3159964A1
(en)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
IL301266A
(en)
|
2020-10-02 |
2023-05-01 |
Genentech Inc |
Process for preparing biheteroaryl compounds and their crystalline forms
|
EP4229082A1
(de)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Alpha-synuclein bindende antikörper zur therapie und diagnose
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|